Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

Marso S. P.
Mcguire D. K.
Zinman B.
Poulter N. R.
Emerson S. S.
Pieber T. R.
Pratley R. E.
Haahr P. -M.
Lange M.
Brown-Frandsen K.
Moses A.
Skibsted S.
Kvist K.
Buse J. B.
Buscemi S

January 2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adu...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Marso, Stiven P.
McGuire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Haahr, Poul-Martin
Lange, Martin
Brown-Frandsen, Kirstine
Moses, Alan
Skibsted, Simone
Kvist, Kajsa
Buse, John B.

January 2017

BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in ad...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Marso, Steven P.
Mcguire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Haahr, Poul-Martin
Lange, Martin
Brown-Frandsen, Kirstine
Moses, Alan
Skibsted, Simon
Kvist, Kajsa
Buse, John B.

January 2017

Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adoles...

ORIGINAL RESEARCH Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials

Jiten Vora
Torsten Christensen
Azhar Rana
Steve C. Bain

January 2014

The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: Ins...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

Hollander, Priscilla
King, A.B.
Del Prato, S.
Sreenan, S.
Balci, M.K.
Muñoz-Torres, M.
Rosenstock, J.
Hansen, C.T.
Niemeyer, M.
Garber, A.J.

January 2015

The aim of the present study was to compare the long-term safety and efficacy of insulin degludec wi...

Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

Hollander, Priscilla
King, A. B.
Sreenan, S.
Balci, M. K.
Muñoz Torres, M.
Rosenstock, J.
Hansen, C. T.
Niemeyer, M.
Garber, A. J.
DEL PRATO, STEFANO

January 2015

The aim of the present study was to compare the long-term safety and efficacy of insulin degludec wi...

Articles Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Bernard Zinman
Greg Fulcher
Paturi V Rao
Nihal Thomas
Lars A Endahl
Thue Johansen
Rebecka Lindh
Andrew Lewin
Julio Rosenstock
Michel Pinget
Chantal Mathieu

January 2011

Summary Background Insulin degludec is a new basal insulin that forms soluble multihexamer assemblie...

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

Mathieu, Chantal
Hollander, Priscilla
Miranda-Palma, Bresta
Cooper, John
Franek, Edward
Russell-Jones, David
Larsen, Jens
Tamer, Søren Can
Bain, Stephen C
NN1250-3770 (BEGIN: Flex T1) Trial Investigators

March 2013

This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying ...

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes

Rendell M

April 2017

Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investig...

Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

Marso S. P.
Mcguire D. K.
Zinman B.
Poulter N. R.
Emerson S. S.
Pieber T. R.
Pratley R. E.
Haahr P. -M.
Lange M.
Brown-Frandsen K.
Moses A.
Skibsted S.
Kvist K.
Buse J. B.
Buscemi S

January 2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adu...

Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

Marso S. P.
Mcguire D. K.
Zinman B.
Poulter N. R.
Emerson S. S.
Pieber T. R.
Pratley R. E.
Haahr P. -M.
Lange M.
Brown-Frandsen K.
Moses A.
Skibsted S.
Kvist K.
Buse J. B.
Buscemi S

January 2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adu...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Marso, Stiven P.
McGuire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Haahr, Poul-Martin
Lange, Martin
Brown-Frandsen, Kirstine
Moses, Alan
Skibsted, Simone
Kvist, Kajsa
Buse, John B.

January 2017

BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in ad...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Marso, Steven P.
Mcguire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Haahr, Poul-Martin
Lange, Martin
Brown-Frandsen, Kirstine
Moses, Alan
Skibsted, Simon
Kvist, Kajsa
Buse, John B.

January 2017

Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adoles...

ORIGINAL RESEARCH Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials

Jiten Vora
Torsten Christensen
Azhar Rana
Steve C. Bain

January 2014

The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: Ins...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan, Véronique
Gouet, Didier
Marre, Michel
Renard, Eric

December 2013

International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration o...

Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

Hollander, Priscilla
King, A.B.
Del Prato, S.
Sreenan, S.
Balci, M.K.
Muñoz-Torres, M.
Rosenstock, J.
Hansen, C.T.
Niemeyer, M.
Garber, A.J.

January 2015

The aim of the present study was to compare the long-term safety and efficacy of insulin degludec wi...

Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

Hollander, Priscilla
King, A. B.
Sreenan, S.
Balci, M. K.
Muñoz Torres, M.
Rosenstock, J.
Hansen, C. T.
Niemeyer, M.
Garber, A. J.
DEL PRATO, STEFANO

January 2015

The aim of the present study was to compare the long-term safety and efficacy of insulin degludec wi...

Articles Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Bernard Zinman
Greg Fulcher
Paturi V Rao
Nihal Thomas
Lars A Endahl
Thue Johansen
Rebecka Lindh
Andrew Lewin
Julio Rosenstock
Michel Pinget
Chantal Mathieu

January 2011

Summary Background Insulin degludec is a new basal insulin that forms soluble multihexamer assemblie...

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

Mathieu, Chantal
Hollander, Priscilla
Miranda-Palma, Bresta
Cooper, John
Franek, Edward
Russell-Jones, David
Larsen, Jens
Tamer, Søren Can
Bain, Stephen C
NN1250-3770 (BEGIN: Flex T1) Trial Investigators

March 2013

This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying ...

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes

Rendell M

April 2017

Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investig...

Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

Marso S. P.
Mcguire D. K.
Zinman B.
Poulter N. R.
Emerson S. S.
Pieber T. R.
Pratley R. E.
Haahr P. -M.
Lange M.
Brown-Frandsen K.
Moses A.
Skibsted S.
Kvist K.
Buse J. B.
Buscemi S

January 2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adu...

Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

Marso S. P.
Mcguire D. K.
Zinman B.
Poulter N. R.
Emerson S. S.
Pieber T. R.
Pratley R. E.
Haahr P. -M.
Lange M.
Brown-Frandsen K.
Moses A.
Skibsted S.
Kvist K.
Buse J. B.
Buscemi S

January 2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adu...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Marso, Stiven P.
McGuire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Haahr, Poul-Martin
Lange, Martin
Brown-Frandsen, Kirstine
Moses, Alan
Skibsted, Simone
Kvist, Kajsa
Buse, John B.

January 2017

BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in ad...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Marso, Steven P.
Mcguire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Haahr, Poul-Martin
Lange, Martin
Brown-Frandsen, Kirstine
Moses, Alan
Skibsted, Simon
Kvist, Kajsa
Buse, John B.

January 2017

Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adoles...

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Abstract

Extracted data

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Abstract

Extracted data

Related items

Related items